DDInter1285 DDInter1763
A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Nevirapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Nevirapine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Nevirapine {u} (Compound) causes {v} (Side Effect) Face oedema
Face oedema {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Nevirapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Nevirapine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Nevirapine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) covaries with {v} (Gene) YRDC
YRDC {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Nevirapine {u} (Compound) causes {v} (Side Effect) Face oedema
Face oedema {u} (Side Effect) is caused by {v} (Compound) Tacrolimus
Tacrolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Nevirapine {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) downregulates {v} (Gene) AGL
AGL {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Nevirapine {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) regulates {v} (Gene) KLHDC2
KLHDC2 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Nevirapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Nevirapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Nevirapine (Compound) causes Face oedema (Side Effect) and Face oedema (Side Effect) is caused by Temsirolimus (Compound)
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Nevirapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Nevirapine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) covaries with YRDC (Gene) and YRDC (Gene) is downregulated by Temsirolimus (Compound)
Nevirapine (Compound) causes Face oedema (Side Effect) and Face oedema (Side Effect) is caused by Tacrolimus (Compound) and Tacrolimus (Compound) resembles Temsirolimus (Compound)
Nevirapine (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) downregulates AGL (Gene) and AGL (Gene) is upregulated by Temsirolimus (Compound)
Nevirapine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) regulates KLHDC2 (Gene) and KLHDC2 (Gene) is upregulated by Temsirolimus (Compound)
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)